Cortisol is involved in the regulation of adipose-tissue differentiation, function and distribution, and in excess causes abdominal obesity. At the level of the brain, cortisol secretion is partly controlled by g-aminobutyric acid (GABA), which is the major inhibitory neurotransmitter in the vertebrate brain, and acts by binding to GABA A receptors. METHOD: We examined the potential impact of a 1519T > C polymorphism in the GABA A a6 receptor subunit (GABRA6) gene on obesity and obesity-related phenotypes as well as circulating hormones, including salivary cortisol in 284 unrelated Swedish men born in 1944. The subjects were genotyped by using PCR amplification of the 3' non-coding region of the GABRA6 gene followed by digestion with the restriction enzyme AlwNI. RESULTS: The frequency of allele T was 0.54 and 0.46 for allele C. Carriers for the T allele (n ¼ 211) had borderline significantly higher waist-to-hip ratio (P ¼ 0.094) and abdominal sagittal diameter (P ¼ 0.084) compared to homozygotes for the C allele (n ¼ 56). The homozygotes for the T allele had, in comparison to heterozygotes, significantly (P ¼ 0.004 -0.024) higher mean cortisol levels at 11:45 am, and 30, 45 and 60 min after a standardized lunch and, finally, at 5:00 pm. In addition, T=T subjects had significantly (P ¼ 0.031) higher diurnal cortisol secretion compared to T=C subjects. Other hormones, glucose and serum lipids were not different across the genotype groups. CONCLUSION: These findings suggest a role of the 1519T > C polymorphism in GABRA6 in the predisposition to hypercortisolism and perhaps abdominal obesity. The pathophysiology may involve various environmental factors, particularly stress, that destabilize the GABA -hypothalamic -pituitary -adrenal systems in those with genetic vulnerability.
Introduction
The hypothalamic -pituitary -adrenal (HPA) axis plays a central role in homeostatic processes. 1 The presence of a continuously changing and sometimes threatening external environment may, when the challenge exceeds a threshold, activate the HPA axis, with a resulting increase in plasma cortisol. Endocrine feedback regulation balances the central afferent signals, which allow the HPA axis to keep cortisol levels within an optimal range. 1 However, if the HPA axis becomes poorly regulated with disruption of central regulatory systems and increased cortisol secretion, the development of visceral obesity, insulin resistance, dyslipidemia and hypertension may occur.
2,3
The hypothalamus has extensive and complex neural connections, and receives afferent regulatory signals from different parts of the brain. Stimulatory inputs arise from the suprachiasmatic nucleus, the amygdala and the raphe nuclei, 4, 5 while inhibitory inputs originate from the hippocampus and the locus coeruleus. 6, 7 The inhibitory effects are exerted mainly by g-aminobutyric acid (GABA). 8 GABA is the major inhibitory neurotransmitter in the vertebrate brain, and acts by binding to the GABA A receptors, which are hetero-oligomeric chloride channels that are modulated among others by cortisol and benzodiazepines. 9 To date, at least 16 human GABA A receptor cDNA have been cloned, including the GABA A a6 receptor subunit. 9 Clinical evidence suggests that alprazolam, a benzodiazepine that activates GABAergic receptors, inhibits the activity of the HPA axis. 10, 11 In obese subjects, pretreatment with alprazolam blunts the HPA axis response to pharmacological challenge tests. 12 Recently, a novel single nucleotide polymorphism (SNP) in the 3' non-coding region of the GABA A a6 receptor subunit (GABRA6) gene has been described. 13 DNA sequencing has shown that it is a T to C substitution resulting in the loss of an AlwNI restriction site at nucleotide 1519. 13 The GABRA6 gene is located on chromosome 5q31.1-q35. 14 The AlwNI SNP at the GABRA6 gene was found to be associated with alcohol dependence and Korsakoff's psychosis. 13 Ethanol and benzodiazepines share many pharmacological properties and the chronic consumption of alcohol, similar to that of benzodiazepines, is linked to GABAergic neurotransmission. 15 With this background, we addressed the hypothesis that the 1519T > C variant of the GABRA6 gene may influence obesity and obesity-related phenotypes as well as circulating hormones, including salivary cortisol.
Subjects and methods

Subjects
In the present study, we recruited the subjects from an ongoing cohort study of men born in 1944. 16, 17 The study was initiated in 1992. Based on self-measured waist-to-hip ratio (WHR), the following three subgroups, each of 150 men, were selected for further studies: the lowest ( 0.885) and the highest values ( ! 1.01) as well as men around the arithmetic mean (0.94 -0.96). We examined these men in 1995 at the age of 51 y, and 284 (63%) volunteered to participate. 18, 19 Nine subjects refused to be involved in the genetic studies, and in eight subjects the amount of blood sample was not sufficient to conduct genetic analysis. All men gave written informed consent before participating in the study, which was approved by the Göteborg University Ethics Committee.
Phenotypic measurements
Body mass index (BMI, kg=m 2 ), WHR, and abdominal sagittal diameter were measured as described before. 18, 19 Salivary cortisol was measured repeatedly over a random working day as described previously. 18 Endocrine measurements, besides cortisol, included plasma levels of testosterone, insulin-like growth factor I, and leptin as previously described. 18, 19 Insulin, glucose, triglycerides, and total, high-and low-density lipoprotein cholesterol were measured in an overnight fasting state as described. 18, 19 The serum lipids were determined by an enzymatic procedure with the Cobas Fara II analyzer (Roche Molecular Biochemicals, Mannheim, Germany).
Genotyping
Genotyping of the 1519T > C SNP was carried out by PCR-RFLP. Genomic leukocyte DNA (150 ng in a final volume of 10 ml) was amplified by PCR using the following primers: 5'-GGA GGC ACC AGT AAA ATA GAC CAG-3' and 5'-AAT ACT GAA CAA TGG AAG ACA AAA-3'. 13 The primers amplified a product of 423 bp. The PCR conditions were: an initial denaturation step at 94 C for 3 min, followed by 35 cycles of denaturation at 94 C for 30 s, annealing at 53 C for 30 s, and extension at 72 C for 30 s, with a final extension of 10 min at 72 C. The PCR reaction product was digested at 37 C overnight with 5 U of the restriction enzyme AlwNI (New England Biolabs, Beverly, MA, USA), generation two fragments of 257 and 166 bp when the T allele is present. The fragments were separated on a 2% agarose gel.
Statistical analysis
All statistical analyses were performed using SPSS for Windows, release 10.0 (SPSS Inc., Chicago, IL, USA). P-values are two-sided throughout, and a P < 0.05 was considered significant. The results are presented as mean and standard deviation (s.d.). Data comparisons were carried out with the General Linear Model, with genotype as independent factors and BMI and WHR as covariates. All P-values were adjusted for multiple tests by using the Spjotvoll -Stoline post hoc correction. 20 
Results
The frequency of allele T was 0.54 and that of the C allele 0.46. The genotype frequencies were 28.8, 50.2 and 21.0% for T=T, T=C and C=C, respectively. The observed genotype frequencies were in a Hardy -Weinberg equilibrium. Table 1 presents the differences in obesity-related phenotypes among the GABRA6 genotypes. Since these variables are highly influenced by obesity and body fat distribution, the results were adjusted for BMI and WHR whenever appropriate. Carriers for the T allele had borderline significantly higher WHR (P ¼ 0.094) and abdominal sagittal diameter (P ¼ 0.084) compared to homozygotes for the C allele. Hormones, glucose and serum lipids were not different across the genotype groups (all adjusted for BMI and WHR). Table 2 shows the differences in salivary cortisol measurements by genotype. The homozygotes for the T allele had, in comparison to heterozygotes, significantly (P ¼ 0.004 -0.024) higher mean cortisol levels at 11:45 am, and 30, 45 and 60 min after a standardized lunch and, finally, at 5:00 pm. In addition, T=T subjects had significantly (P ¼ 0.031) higher diurnal cortisol secretion compared to T=C subjects.
Discussion
In developed societies, metabolic and circulatory disorders such as abdominal obesity, type 2 diabetes, dyslipidemia and GABRA6, abdominal obesity and cortisol R Rosmond et al hypertension rarely occur in isolation, but are typically part of a complex phenotype of metabolic abnormalities usually referred to as the Metabolic Syndrome. 2 The Metabolic Syndrome is usually defined as a set of risk factors that cluster in some people. 21, 22 The risk factors include elevated insulin levels (insulin resistance), abdominal obesity, high levels of both LDL cholesterol and triglycerides, and hypertension. In addition to insulin resistance, abdominal obesity in adults is a key contributor to the development of the Metabolic Syndrome. There are currently several important theories that attempt to explain the causes of abdominal obesity. Studies of twins and families suggest that about 40 -80% of the variation in human obesity can be ascribed to genetic factors. 23 Most variation in human obesity-related phenotypes is due to a limited number of common genetic variations that interact with the environment to produce the final phenotype. 23 The number of genes, markers and chromosomal regions that have been associated or linked with human obesity-related phenotypes is now well above 200 and continues to increase. 24 In the present study, we found a new polymorphism potentially associated with abdominal obesity. Carriers for the T allele tended to have both elevated WHR and abdominal sagittal diameter (Table 1) . In animal models, the obese Zucker rat possesses altered brain GABAergic mechanisms that contribute to their overeating. 25, 26 In subjects with Prader -Willi syndrome, the mean level of plasma GABA was found to be two to three times higher than in retarded nonobese controls. 27 Although a role of GABA in human obesity has not, to our knowledge, been previously described, these studies suggest that GABAergic tonic inhibition may be potentially involved.
In addition to GABA, complex interactions among various neurotransmitters and neuromodulators involved in the regulation of energy balance, such as leptin, neuropeptide Y and several hormones, including cortisol, may directly or indirectly participate in the GABAergic regulation. Interestingly, carriers for the T allele had also elevated diurnal cortisol secretion (Table 2 ). These results indicate that the 1519T > C SNP in GABRA6 might be involved in the GABRA6, abdominal obesity and cortisol R Rosmond et al dysfunction of the hypothalamic cortisol homeostasiscontrolling mechanisms within the central nervous system. It is well documented that cortisol contributes to the regulation of adipose-tissue differentiation, function and distribution and, in excess, causes abdominal obesity. 3 Inadequate cortisol secretion is associated with abnormalities in glucose, insulin and lipid metabolism, bringing the importance of the HPA axis in the development of abdominal obesity to the forefront. 3 In summary, we found that a 1519T > C polymorphism of the GABRA6 gene is associated with elevated salivary cortisol levels and potentially abdominal obesity. As this polymorphism is not located in a coding region of the GABA A a6 receptor subunit gene, its functional role, if any, is uncertain. Further studies are required to replicate these preliminary findings and to define the biological effects of this polymorphism.
